- Home
- DMF vs ELDN Comparison
DMF vs ELDN Comparison
Compare DMF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- ELDN
- Stock Information
- Founded
- DMF 1988
- ELDN 2004
- Country
- DMF United States
- ELDN United States
- Employees
- DMF N/A
- ELDN N/A
- Industry
- DMF Finance/Investors Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- DMF Finance
- ELDN Health Care
- Exchange
- DMF Nasdaq
- ELDN Nasdaq
- Market Cap
- DMF 149.3M
- ELDN 140.3M
- IPO Year
- DMF N/A
- ELDN N/A
- Fundamental
- Price
- DMF $7.23
- ELDN $4.07
- Analyst Decision
- DMF
- ELDN Strong Buy
- Analyst Count
- DMF 0
- ELDN 1
- Target Price
- DMF N/A
- ELDN $16.00
- AVG Volume (30 Days)
- DMF 60.7K
- ELDN 1.0M
- Earning Date
- DMF 01-01-0001
- ELDN 11-12-2024
- Dividend Yield
- DMF 2.66%
- ELDN N/A
- EPS Growth
- DMF N/A
- ELDN N/A
- EPS
- DMF 0.15
- ELDN N/A
- Revenue
- DMF N/A
- ELDN N/A
- Revenue This Year
- DMF N/A
- ELDN N/A
- Revenue Next Year
- DMF N/A
- ELDN N/A
- P/E Ratio
- DMF $45.13
- ELDN N/A
- Revenue Growth
- DMF N/A
- ELDN N/A
- 52 Week Low
- DMF $5.37
- ELDN $1.11
- 52 Week High
- DMF $6.79
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- DMF 49.40
- ELDN 51.95
- Support Level
- DMF $7.18
- ELDN $3.76
- Resistance Level
- DMF $7.27
- ELDN $4.17
- Average True Range (ATR)
- DMF 0.08
- ELDN 0.39
- MACD
- DMF 0.01
- ELDN -0.15
- Stochastic Oscillator
- DMF 66.07
- ELDN 18.45
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.